Clinical Trial Update: Efficacy and Safety of Immunosuppression, Caplacizumab and Plasma Infusion Without Therapeutic Plasma Exchange in Immune-mediated Thrombotic Thrombocytopenic Purpura [NA]

View source ↗

Summary

A clinical trial evaluating immunosuppression, caplacizumab, and plasma infusion without therapeutic plasma exchange for immune-mediated thrombotic thrombocytop…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombotic Microangiopathy
• Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• CABLIVI (CAPLACIZUMAB)

Snippet

Sponsor: University Hospital, Rouen | Conditions: Thrombotic Microangiopathies | NA | Status: RECRUITING